Statement by Chip Davis, President and CEO, GPhA, Regarding the Launch of the First Biosimilar
Contact: Steve Arnoff 202.249.7113
WASHINGTON, DC (Sept. 3, 2015) –
“The Biosimilars Council, a division of GPhA, is very pleased that a federal appeals court has cleared the way for patients to access the first FDA-approved biosimilar. The launch of Zarxio is a victory for all champions of improving access and affordability in healthcare.
Now, regulatory agencies must ensure that policies pertaining to reimbursement, interchangeability, and other issues continue to foster the development of a robust biosimilars marketplace ensure the availability of these affordable alternatives to costly brand biologics, and delivers cost savings for patients and America’s healthcare system.
The Biosimilars Council looks forward to working with all stakeholders to ensure the creation of a positive environment for patient access to Zarxio and the wave of biosimilars awaiting approval. We are committed to our continued efforts to educate providers, prescribers, and patients about the safety and quality profiles of these new medicines.”
About the Biosimilars Council
The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.
GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 86 percent of the prescriptions dispensed in the U.S. but consume just 27 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.